Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circumstances and triggering factors for major arrhythmic events in Brugada Syndrome patients without spontaneous type 1 ST elevation.

Heart rhythm·2026
Same author

Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study.

ESC heart failure·2026
Same author

Duration of heart failure as a determinant of outcomes after left ventricular assist device implantation: an international multicenter study.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Clinical Impact and Prediction of Early Electrical Storm in Patients With Left Ventricular Assist Device.

JACC. Clinical electrophysiology·2026
Same author

Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study.

European heart journal. Digital health·2026
Same author

Pulmonary vein isolation alone vs adjunctive ablation for first persistent atrial fibrillation: A real-world target-trial emulation.

Heart rhythm·2026

Related Experiment Video

Updated: Jun 2, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

[When do you implant a pacemaker in myotonic dystrophy?].

Dominique Babuty1, Bénédicte Lallemand, Valérie Laurent

  • 1Université François-Rabelais, CHU de Tours, hôpital Trousseau, 37044 Tours, France. d.babuty@chu-tours.fr

Presse Medicale (Paris, France : 1983)
|May 10, 2011
PubMed
Summary

Myotonic dystrophy patients face increased sudden death risk from cardiac issues. Prophylactic pacemakers are recommended for high-risk individuals, guided by ECG and electrophysiologic studies.

More Related Videos

Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Related Experiment Videos

Last Updated: Jun 2, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Area of Science:

  • Cardiology
  • Genetics
  • Neurology

Context:

  • Myotonic dystrophy is the most common adult hereditary muscular dystrophy, linked to DMPK gene mutations.
  • It causes systemic complications including cardiac arrhythmias and conduction disturbances.
  • Patients experience reduced lifespan and high sudden death rates.

Purpose:

  • To identify risk factors for sudden death in myotonic dystrophy patients.
  • To evaluate the utility of non-invasive tests for risk stratification.
  • To guide prophylactic pacemaker and defibrillator implantation decisions.

Summary:

  • Sudden death in myotonic dystrophy arises from atrio-ventricular block, ventricular arrhythmias, or non-cardiac factors.
  • High-grade atrio-ventricular block warrants pacemaker implantation.
  • Prophylactic pacemaker implantation should be considered in asymptomatic patients with a prolonged HV interval (≥70 ms) on electrophysiologic study.
  • Implantable cardiac defibrillators are indicated for spontaneous ventricular tachycardia or reduced left ventricular ejection fraction.

Impact:

  • This research aids in early identification of myotonic dystrophy patients at high risk of sudden cardiac death.
  • It supports the prophylactic implantation of pacemakers and defibrillators, potentially improving survival rates.
  • Clinical evaluation, resting ECG, and SA ECG are crucial non-invasive tools for patient selection.